The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Open accessAbstract
Recombinant Adeno-associated virus (rAAV) is one of the main delivery vectors for gene therapy. To assess immunogenicity, toxicity, and features of AAV gene therapy in clinical settings, a meta-analysis of 255 clinical trials was performed. A total of 7,289 patients are planned to be dosed. AAV2 was the most dominantly used serotype (29.8%, n=72), and 8.3% (n=20) of trials used engineered capsids. 38.7% (n=91) of trials employed neutralizing antibody assays for patient enrollment, while 15.3% (n=36) used ELISA-based total antibody assays. However, there was high variability in the eligibility criteria with cut-off tiers ranging from 1:1 to 1:1,600. To address potential immunogenicity, 46.3% (n=118) of trials applied immunosuppressants (prophylactic or reactive), while 32.7% (n=18) of CNS and 37.5% (n=24) of ocular-directed trials employed immunosuppressants, possibly due to the immune-privileged status of CNS and retina. There were a total of 11 patient deaths across 8 trials, and 18 out of 30 clinical holds were due to toxicity findings in clinical studies. 30.6% (n=78) of trials had treatment-emergent serious adverse events (TESAEs), with hepatotoxicity and thrombotic microangiopathy (systemic delivery) and neurotoxicity (CNS delivery) being the most prominent. Additionally, the durability of gene therapy may be impacted by two distinct decline mechanisms: 1) rapid decline presumably due to immune responses; or 2) gradual decline due to vector dilution. The durability varied significantly depending on disease indication, dose, serotypes, and patient individuals. Most CNS (90.0%) and muscle trials (73.3%) achieved durable transgene expression, while only 43.6% of ocular trials had sustained clinical outcomes. The rAAV production system can affect rAAV quality and thus immunogenicity and toxicity. Out of 186 trials that have disclosed production system information, 63.0% (n=126) of trials used the transient transfection of the HEK293/HEK293T system, while 18.0% (n=36) applied the baculovirus/Sf9 (rBac/Sf9) system. There were no significant differences in TESAEs and durability between AAV generated by rBac/Sf9 and HEK293/HEK293T systems. In summary, rAAV immunogenicity and toxicity poses significant challenges for clinical development of rAAV gene therapies, and it warrants collaborative efforts to standardize monitoring/measurement methods, design novel strategies to overcome immune responses, and openly share relevant information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In severe cases, GTAU has, albeit uncommonly, led to the permanent loss of visual acuity, and long-term efficacy of treatment has only been achieved in 43.6% of ocular gene therapy trials.9”
From Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444 · cited 2×
“Additionally, the search was broadened to (1) company press releases (2), company official documents (SEC and IPO filings), (3) presentations in research conferences, (4) publications in journal articles, and (5) company websites.”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 5×
“Another 6 trials are associated with Zolgensma, which uses self-complementary AAV9 and have been approved as a commercialized product (35).”
BackgroundInfluentialManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“Additionally, the search was broadened to (1) company press releases (2), company official documents (SEC and IPO filings), (3) presentations in research conferences, (4) publications in journal articles, and (5) company websites.”
BackgroundSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Luxturna (32), and Upstaza (33) and one conditional approval Roctavian (34) in the USA and/or EU.”
BackgroundLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061 · cited 1×
“For instance, an engineered capsid selected from a C57BL/6J mice strain penetrates the blood brain barrier efficiently (90).”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814 · cited 1×
“The most prominent TESAEs were hepatotoxicity (43), TMA (44), and neurotoxicity (40), while DRG toxicity attracted much attention recently (38, 47).”
BackgroundWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 1×
“Serum prevalence studies suggested a significant portion of the human population had high levels of rAAV neutralizing antibodies (13).”
Background
Research works printed but not linked: 1
- Bonnemann, 2020, AAV related immunological safety and toxicity: Preliminary clinical observations in the GAN and MTM1 trials
Cited by
AAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 101
“In 2022, there were 20 trials using 10 unique engineered capsids as reported by Shen et al. 270 Currently, there are 39 trials utilizing 15 unique engineered capsids, indicating a substantial upswing in the utilization of the emerging novel capsids in the past 2 years.”
InfluentialSevigny, J., Uspenskaya, O., Heckman, L. D., Wong, L. C., Hatch, D. A., Tewari, A., Vandenberghe, R. R., Irwin, D. J., Saracino, D., Ber, I. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02973-0 · Cited by 90
RNA Therapeutics for the Cardiovascular System
Dzau, V. J., & Hodgkinson, C. P. (2024) · Circulation · doi:10.1161/circulationaha.123.067373 · Cited by 79
“58 In addition to questions regarding their toxicity, AAVs are often cleared by preexisting immunity.”
BackgroundAAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 73
“Until June 1, 2022, AAV-mediated gene therapy has been or is being evaluated in a total of 255 clinical trials [6].”
BackgroundSelf-citationKim, Y., Landstrom, A. P., Shah, S. H., Wu, J. C., & Seidman, C. E. (2024) · Circulation · doi:10.1161/cir.0000000000001296 · Cited by 91
“46,47 Adverse effects appear greatest among patients receiving high-dose AAV.”
Metadata
- Authors
- Shen, W., Liu, S., & Ou, L.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Ou, Li
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-10-27
- Volume
- 13
- Pages
- 1001263-1001263
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC9647052
- OpenAlex
- W4307633692
- Cited by
- 173
- References
- 88
- Citations by year
- 2026: 40 · 2025: 60 · 2024: 47 · 2023: 26
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Update notices
- corrigendum (2023-01-18)
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- recombinant adeno-associated virus, AAV gene therapy, immunogenicity, toxicity, neutralizing antibodies, immunosuppression, hepatotoxicity, thrombotic microangiopathy, neurotoxicity, ocular gene therapy, CNS gene therapy, HEK293 cells
- MeSH terms
- Dependovirus, Genetic Vectors, Humans, Immunosuppressive Agents, Genetic Therapy, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. https://app.cochat.ai/papers/10.3389/fimmu.2022.1001263
- The paper
- Shen, W., Liu, S., & Ou, L. (2022). rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.1001263
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.